Back to previous section

Cambridge Cognition FY revenues seen at no less than £10m

Brain health software group Cambridge Cognition said on Tuesay that full-year revenues were expected to be no less than £10.0m, while adjusted underlying earnings was seen at close to breakeven.

Cambridge Cognition

Source: Sharecast

Cambridge Cognition noted that following its operational reorganisation at the end of Q3, the highest levels of both sales orders and book-to-bill ratio in FY24 was recorded in October.

Encouragingly, sales orders secured during H2 included an increasing number of multi-product contracts, particularly including eCOA, AQUA and voice recognition, which were brought into the portfolio through the Winterlight and eClinicalHealth acquisitions. In addition, Cambridge Cognition there was an increasing number of repeat orders from top-tier pharmaceutical customers.

However, the AIM-listed group stated that with most of its new sales orders secured in Q4, much of the revenue will be recognised in FY25 or later.

Cambridge Cognition also highlighted that it now had greater revenue visibility into FY25, with a strengthened order book of £13.5m and a growing sales pipeline of over £34.0m.

As of 1335 GMT, Cambridge Cognition shares were up 6.14% at 31.31p.

Reporting by Iain Gilbert at Sharecast.com

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Chart not available

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Lloyds Bank is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Lloyds and Lloyds Bank are trading names of Halifax Share Dealing Limited. The Lloyds Bank Direct Investments Service is operated by Halifax Share Dealing Limited. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Registered in England and Wales no. 3195646. Halifax Share Dealing Limited is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2025 Refinitiv, an LSEG business. All rights reserved.